Undisclosed Immune Cell Depleter
Undisclosed
Key Facts
About Hillstar Bio
Hillstar Bio is a private, preclinical-stage biotech developing targeted immunotherapies designed to deplete disease-causing immune cells in autoimmune conditions. Its lead program, HSB-101, targets TRBV9+ T cells for axial spondyloarthritis (AxSpA) and is anticipated to enter Phase 1 trials in 2026. The company is backed by prominent venture capital firms and leverages a strategy of antibody engineering against validated genetic markers to de-risk development and move beyond the chronic, broad immunosuppression of current standard-of-care treatments.
View full company profileAbout Hillstar Bio
Hillstar Bio is a private, preclinical-stage biotech developing targeted immunotherapies designed to deplete disease-causing immune cells in autoimmune conditions. Its lead program, HSB-101, targets TRBV9+ T cells for axial spondyloarthritis (AxSpA) and is anticipated to enter Phase 1 trials in 2026. The company is backed by prominent venture capital firms and leverages a strategy of antibody engineering against validated genetic markers to de-risk development and move beyond the chronic, broad immunosuppression of current standard-of-care treatments.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |